Literature DB >> 9278298

A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.

H J Ahn1, S Maruo, M Tomura, J Mu, T Hamaoka, K Nakanishi, S Clark, M Kurimoto, H Okamura, H Fujiwara.   

Abstract

IL-12 and IFN-gamma-inducing factor (IGIF) have the capacity to stimulate IFN-gamma production by T cells. Using an IL-12-responsive T cell clone, 2D6, we investigated how these two cytokines collaborate for IFN-gamma production. 2D6 obtained from cultures containing rIL-12 produced IFN-gamma in response to rIGIF. 2D6 from cultures deprived of IL-12 for 24 h produced only marginal levels of IFN-gamma production following stimulation with either rIL-12 or rIGIF alone. However, simultaneous stimulation of these 2D6 cells with both cytokines resulted in strikingly enhanced levels of IFN-gamma production. 2D6 could also be maintained in the presence of rIL-2 instead of rIL-12. 2D6 lines maintained with rIL-12 (2D6(IL-12)) or rIL-2 (2D6(IL-2)) exhibited differential IGIF responsiveness: both lines responded similarly to rIL-2 or rIL-12, whereas the 2D6(IL-12) or 2D6(IL-2) exhibited high or marginal IGIF responsiveness, respectively. The 2D6(IL-12) line expressed IGIF receptor (IGIFR), whereas the 2D6(IL-2) did not. Overnight exposure of the 2D6(IL-12) to rIL-2 reduced IGIFR expression and conversely, exposure of the 2D6(IL-2) to rIL-12 restored IGIFR expression. IGIFR expression by these 2D6 lines correlated with the capacity to produce IFN-gamma in response to rIGIF. Purified naive T cells stimulated with anti-CD3 plus anti-CD28 mAb and subsequently cultured with rIL-12 were also found to express IGIFR and induce enhanced IFN-gamma production following IGIF stimulation. These results indicate that the induction of IGIFR by IL-12 represents one of the mechanisms underlying the synergy between IL-12 and IGIF in IFN-gamma production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278298

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Anti-CD3 sFv/IL-18 fusion DNA for allergy therapy.

Authors:  Maria Salagianni; David M Kemeny
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

2.  Regulation of innate CD8+ T-cell activation mediated by cytokines.

Authors:  Bailey E Freeman; Erika Hammarlund; Hans-Peter Raué; Mark K Slifka
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

3.  Stimulatory and costimulatory effects of IL-18 directed to different small intestinal CD43 T cell subsets.

Authors:  Dina Montufar-Solis; Heuy-Ching Wang; John R Klein
Journal:  J Leukoc Biol       Date:  2007-08-16       Impact factor: 4.962

4.  IL-18 is required for self-reactive T cell expansion in NOD mice.

Authors:  Annette M Marleau; Nora E Sarvetnick
Journal:  J Autoimmun       Date:  2011-03-16       Impact factor: 7.094

5.  Expression of IL-18 by Mycobacterium avium-infected human monocytes; association with M. avium virulence.

Authors:  H Shiratsuchi; J J Ellner
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 6.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

7.  Increased pleural soluble fas ligand (sFasL) levels in tuberculosis pleurisy and its relation with T-helper type 1 cytokines.

Authors:  Ferah Budak; Esra Kunt Uzaslan; Sengül Cangür; Güher Göral; Haluk Barbaros Oral
Journal:  Lung       Date:  2008-07-29       Impact factor: 2.584

8.  Interleukin-18 protects mice against acute herpes simplex virus type 1 infection.

Authors:  N Fujioka; R Akazawa; K Ohashi; M Fujii; M Ikeda; M Kurimoto
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 9.  The role of interleukin-18 in the metabolic syndrome.

Authors:  Marius Trøseid; Ingebjørg Seljeflot; Harald Arnesen
Journal:  Cardiovasc Diabetol       Date:  2010-03-23       Impact factor: 9.951

10.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.